Newborn screening was first applied to the detection of phenylketonuria (PKU) by a bacterial inhibition assay pioneered in 1961 by Guthrie, who was also responsible for the introduction of the use of a dried blood sample . This was followed by further bacterial inhibition assays to detect other aminoacidopathies (maple syrup urine disease, homocystinuria, urea cycle disorders, etc.), but only screening for PKU was widely adopted. In 1975 Dussault described screening for congenital hypothyroidism (CH) , and since then other disorders covered in some screening programmes have included congenital adrenal hyperplasia, the galactosaemias, cystic fibrosis, biotinidase deficiency, glucose-6-phosphate dehydrogenase deficiency and many others.
|Original language||English (US)|
|Title of host publication||Inborn Metabolic Diseases|
|Subtitle of host publication||Diagnosis and Treatment|
|Publisher||Springer Berlin Heidelberg|
|Number of pages||12|
|State||Published - Jan 1 2012|
ASJC Scopus subject areas